Incidental congenital renal and ureteric anomalies in patients studied for neoplastic diseases

To the Editor: In daily clinical practice, the use of a positron emission tomography/computed tomography (PET/CT) in oncology frequently reveals in various sites of the whole body incidental physiologic, anatomic, benign or pathologic findings [1-4] that may have clinical significance [1-9].

In our patients, fluorine-18 fluorodeoxyglucose (18F-FDG) in a dose of 5.5MBq/kg was administered intravenously and 60min later, a two-dimensional (2D) mode ordered subset-expectation maximization (OS-EM) imaging (with septa) was acquired on a Discovery ST PET/CT scanner (General Electric Company-GE® Milwaukee, WI, USA) with standard CT parameters (80mA, 120kV without contrast; 4min per bed-PET-step of 15cm). The reconstruction was performed in a 128×128 matrix and 60cm field of view. Fluorine-18 fluorodeoxyglucose (18F-FDG)-PET/CT was performed in the fasting state with glucose level lower than 150mg/dL for at least 6h. A written consensus was obtained from all patients before the studies.

We describe five cases of patients mostly studied for neoplastic diseases by 18F-FDG-PET/CT in which we incidentally noticed congenital variants.

The first patient (Fig. 1) had oesophageal carcinoma previously treated by surgery and was examined for a follow-up. The study was negative for neoplastic lesions but revealed high uptake at the right ascending colon probably due to inflammation and an incidental finding of a double left kidney collecting system.

The second patient (Fig. 2) was examined because of fever of unknown origin and suspected for lymphoproliferative disease. A pathological uptake was identified at the right large bowel, probably due to chronic inflammatory bowel disease and also a double right kidney collecting system. No lymphoma was finally diagnosed.

The third patient (Fig. 3) underwent 18F-FDG-PET/CT for staging purposes because of an advanced metastatic right breast cancer; pathological uptake was identified at the left breast mass, left axillary lymph nodes, mediastinal lymph nodes and many hepatic lesions. A right horizontal abdominal ectopic kidney was also identified in the meso-hypogastric part of the abdomen.

The first patient (Fig. 1) had oesophageal carcinoma previously treated by surgery and was examined for a follow-up. The study was negative for neoplastic lesions but revealed high uptake at the right ascending colon probably due to inflammation and an incidental finding of a double left kidney collecting system.

The second patient (Fig. 2) was examined because of fever of unknown origin and suspected for lymphoproliferative disease. A pathological uptake was identified at the right large bowel, probably due to chronic inflammatory bowel disease and also a double right kidney collecting system. No lymphoma was finally diagnosed.

Figure 1. Anterior view (1-A1) and left oblique anterior view at 45° (1-A2) of maximum intensity projection show double left kidney collecting system (arrows). Axial PET (1-B1), CT (1-B2), fused (1-B3) images show lower pelvis (arrows); axial PET (1-C1), CT (1-C2), fused (1-C3) images show upper pelvis (arrows); coronal CT (1-D1;1-E1), PET (1-D2;1-E2) and fused (1-D3;1-E3) images show both pelvis (arrows).

Figure 2. Anterior view (2-A1) and left oblique anterior view at 30° (2-A2) of maximum intensity projection show double left kidney collecting system (arrows). Axial PET (2-D2), CT (2-D1), fused (2-D3), coronal CT (2-C1), PET (2-C2) and fused (2-C3) images show lower pelvis (arrows); axial PET (2-E2), CT (2-E1), fused (2-E3), coronal CT (2-B1), PET (2-B2) and fused (2-B3) images show upper pelvis (arrows).

Figure 3. Anterior view (3-A1) of maximum intensity projection shows horizontal abdominal ectopic kidney (arrow); axial fused (3-C1), CT (3-C2) and PET (3-C3) images, sagittal fused (3-B1), CT (3-B2), and PET (3-B3) images, coronal fused (3-D1), CT (3-D2) and PET (3-D3) images show horizontal ectopic right kidney (arrows).
The fourth patient (Fig. 4) underwent $^{18}$F-FDG-PET/CT scan after surgical resection of uterine carcinoma and chemotherapy. A horseshoe kidney was identified at the central part of the abdomen and also a metastatic abdominal lymph node and the port-a-cath, site of injection.

The fifth patient (Fig. 5) was affected by rhinopharyngeal carcinoma and underwent $^{18}$F-FDG-PET/CT during follow-up. The study was negative for neoplastic lesions but revealed an ectopic left kidney.

Figure 4. Anterior view (4-A1) of maximum intensity projection show horseshoe kidney at the central part of the abdomen (slim arrows); it’s moreover visible secondary lesion at an abdominal lymph-node (big arrow) and the port-a-cath, site of injection (empty arrows). Axial CT (4-C1), fused (4-C2) and PET (4-C3) images, coronal CT (4-B1), fused (4-B2) and PET (4-B3) images show horseshoe kidney (slim arrows).

Figure 5. Anterior view (5-A1) and left lateral view (5-A2) of maximum intensity projection image show ectopic left kidney (big arrow) and normal right kidney slim arrow; axial PET (5-B1), CT (5-B2), fused (5-B3) images show left ectopic kidney (big arrows); axial PET (5-C1), CT (5-C2), fused (5-C3) images show right kidney (slim arrows); coronal CT (5-D1), PET (5-D2), fused (5-D3) images show left ectopic kidney (big arrows; coronal CT (5-E1), PET (5-E2), fused (5-E3) images show right kidney (slim arrows).

Congenital anomalies of the kidney and urinary tract are present in about 10% of the population and account for approximately one-third of all congenital malformations [10]. In our department the prevalence of these anomalies is approximately 3%-5%. Incidental findings on PET/CT images are frequent and often reveal unknown diseases or anatomic variants that are not usually related to the current pathology of the patient [3-9]. It is mandatory to identify and report anatomic variants and potentially unknown malformations for further investigation and treatment.

In conclusion, we present five cases with congenital renal-ureteric anomalies examined by PET/CT for cancer metastases.

Bibliography


Francesco Bertagna¹ MD, Arturo Terzi¹ MD, Claudio Pizzocaro¹ MD, Giovanni Bosio² MD, Giorgio Biasiottò² Biol, Raffaele Giubbini² MD, Thomas Werner³ MD, Abass Alavi4 MD, PhD, DSc.

1. Nuclear Medicine, Spedali Civili di Brescia, Brescia, Italy.
2. Biomedical Technology Department, Brescia, Brescia, Italy.
3. Nuclear Medicine Faculty, University of Brescia, Brescia, Italy.
4. University of Pennsylvania, Medical Center Division of Nuclear Medicine, Philadelphia, USA.

Francesco Bertagna, MD
Department of Nuclear Medicine, Spedali Civili di Brescia, Piazza Spedali Civili, 1, 25123 Brescia, Italy.
Tel.: +39-30-3995468, Fax: +39-30-3995420
E-mail: francesco.bertagna@spedalicivili.brescia.it

Published on line: 22-6-2010

www.nuclmed.gr
Hellenic Journal of Nuclear Medicine • May - August 2010

178